Abstract
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1182/blood-2019-125792
Copy DOIJournal: Blood | Publication Date: Nov 13, 2019 |
Citations: 8 |
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Join us for a 30 min session where you can share your feedback and ask us any queries you have